Clinical trials: Other INI1 Negative Tumors (With PI Approval)

Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

• Active, not recruiting
• Age: 6 months to 40 years
• Phase 2
• Results posted

This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.

Conditions

Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated)

Trial name

NCT04416568

Testing

Nivolumab, Ipilimumab

Where

8 sites in United States

Volunteers

30 people

Sponsor

Dana-Farber Cancer Institute